1-4 of 4
Sule Mine Bakanay, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Plasma Cell Content of Autulogous Grafts, Chemosensitivity to Induction or High Dose Therapy and Pre/Post Transplant PET Negativity Predict Long Term Disease Free Survival in Multiple Myeloma.

Sule Mine Bakanay, MD, Klara Dalva, MD, Berna Elif Koksoy, MD, Erol Ayyildiz, Muhit Ozcan, M.D., Osman Ilhan, MD, Meral Beksac, MD
Journal: Blood
Blood (2012) 120 (21): 3024.
https://doi.org/10.1182/blood.V120.21.3024.3024
Published: 2012
Journal Articles

Kiler Immunoglobulin Receptor(KIR) Ligands Are Associated with At Least Partial (HLA A*03, B*44) or Poorer (HLA B*51, C*04) Response to Thalidomide Among Patients with Multiple Myeloma Treated in Two Turkish Centers

Elif Suyani, MD, Sule Mine Bakanay, MD, Klara Dalva, MD, Ezgi Cakmak, MSc, Rauf Haznedar, MD, Gulsan Sucak, MD, Meral Beksac, MD
Journal: Blood
Blood (2012) 120 (21): 4904.
https://doi.org/10.1182/blood.V120.21.4904.4904
Published: 2012
Journal Articles

Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndrome: A Retrospective Validation From a Single Centre.

Pervin Topcuoglu, MD, Klara Dalva, M.D., Sule Mine Bakanay, MD, Sinem Civriz Bozdag, M.D., Onder Arslan, M.D., Muhit Ozcan, M.D., Mutlu Arat, MD, Meral Beksac, MD, Gunhan Gurman, M.D.
Journal: Blood
Blood (2009) 114 (22): 4846.
https://doi.org/10.1182/blood.V114.22.4846.4846
Published: 2009
Journal Articles

Factors Involved in Response to Thalidomide in Myelodysplastic Syndrome: Impace of HLA and Prognostic Factors

Sule Mine Bakanay, MD, Klara Dalva, MD, Pervin Topcuoglu, MD, Sinem Civriz-Bozdag, MD, Mutlu Arat, MD, Meral Beksac, MD, Gunhan Gurman, MD
Journal: Blood
Blood (2008) 112 (11): 5079.
https://doi.org/10.1182/blood.V112.11.5079.5079
Published: 2008